OBJECTIVE: To study factors associated with @entity137 , final dose, and efficacy of @entity1499 ( @entity1500 ) in @entity1 with @entity309 ( @entity309 ). METHODS: Data were used from a randomised clinical 48 week trial on 411 @entity1 with @entity309 all treated with @entity1500 , comparing folates and placebo. Logistic regression was used to study the relation between baseline variables and various dependent factors, including hepatotoxicity ( @entity493 aminotransferase >/=3 x upper limit of normal), @entity1500 withdrawal, final @entity1500 dose >/=15 mg/week, and @entity1500 efficacy. RESULTS: Addition of folates to @entity1500 treatment was strongly related to the lack of hepatotoxicity. Next to this, high body mass index was related to the occurrence of hepatotoxicity. Prior gastrointestinal (GI) events and younger age were related to the adverse event, @entity294 . Hepatotoxicity and GI adverse events were the main reason for @entity1500 withdrawal, which in turn was associated with the absence of @entity1501 supplementation, body mass index, prior GI events, and female sex. Renal function ( @entity1011 clearance >/=50 ml/min) was not associated with @entity137 . Reaching a final dose of @entity1500 of >/=15 mg/week was related to @entity1501 supplementation and the absence of prior GI events. Efficacy of @entity1500 treatment was associated with low disease activity at baseline, male sex, use of non-steroidal anti-inflammatory drugs (NSAIDs), and lower @entity1011 clearance. CONCLUSIONS: @entity1500 @entity137 , final dose, and efficacy are influenced by @entity1501 supplementation. Baseline characteristics predicting the outcome of @entity1500 treatment are mainly prior GI events, body mass index, sex, use of NSAIDs, and @entity1011 clearance.

Factors associated with XXXX , final dose, and efficacy of @entity1499 in @entity1 with @entity309 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1501 :: ('MESH:D005492', 'Chemical') :: ['folate'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
